Defining a new era of oligonucleotides

Defining a new era of oligonucleotides

Press Releases

Press Releases

  • Mar 29, 2021
    Wave Life Sciences Provides Update on Phase 1b/2a PRECISION-HD Trials
    mHTT results from PRECISION-HD trials do not support further development of WVE-120102 and WVE-120101 No observed change in wtHTT and NfL during trials Advancing Phase 1b/2a trial for WVE-003 (SNP3) program in HD; WVE-003 uses new PN backbone chemistry modifications, which demonstrate improved
  • Mar 19, 2021
    Wave Life Sciences to Present at the Third Annual Stifel CNS Day
    CAMBRIDGE, Mass. , March 19, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno , MD, MBA, President and Chief Executive